Cystatin C in sera of patients with aggressive non-Hodgkin B-cell lymphoma.
OBJECTIVE
To investigate the cystatin C levels in sera of patients with aggressive non-Hodgkin B-cell lymphoma.


METHODS
The levels of cystatin C in sera of lymphoma patients and control group consisted of healthy individuals, were measured by using specific sandwich-type ELISA. For each patient the clinical stage of disease was determined according to Ann Arbor staging system for lymphomas.


RESULTS
Our study shows that mean cystatin C serum level in the patients group (1056 +/- 65 ng/mL) was significantly higher when compared with the mean level of the healthy control group (819 +/- 28 ng/mL) (P = 0.001). Mean cystatin C level of the group with clinical stages III and IV (1255 +/- 109 ng/mL) was significantly elevated when compared with the mean level of the group with clinical stages I and II (896 +/- 51 ng/mL) (P = 0.03).


CONCLUSIONS
This finding points out a connection between inhibitor level and aggressive behaviour of lymphoma and could be considered for further strategies of prognosis of the disease.
Faculty of Pharmacy, University of Tuzla, Bosnia and Herzegovina. adaleta_m@yahoo.com
Adaleta
A
Softić
Lejla
L
Begić
Alma
A
Halilbasić
Janko
J
Kos
D055316:Cystatin C / Q000032:analysis*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D016393:Lymphoma, B-Cell / Q000097:blood* / Q000473:pathology
D055316:Cystatin C